Cubist Systematic Strategies LLC Sells 232,619 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Cubist Systematic Strategies LLC has reduced its stake in Cellebrite DI Ltd. by 42.2%, now owning approximately 317,983 shares valued at $6.18 million.
• Several institutional investors have increased their holdings, with Northern Trust Corp raising its position by 113.6%, now owning 211,994 shares valued at $4.67 million.
• Analysts have lowered price targets for Cellebrite DI; Needham & Company now sets a target of $18.00, down from $24.00, maintaining a "buy" rating.

Cubist Systematic Strategies LLC reduced its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 42.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 317,983 shares of the company's stock after selling 232,619 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.13% of Cellebrite DI worth $6,178,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. bought a new position in shares of Cellebrite DI during the 1st quarter valued at about $60,939,000. Invesco Ltd. increased its stake in Cellebrite DI by 122.1% during the 1st quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock valued at $64,043,000 after purchasing an additional 1,811,757 shares in the last quarter. Handelsbanken Fonder AB grew its stake in shares of Cellebrite DI by 749.9% during the 1st quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock worth $29,508,000 after acquiring an additional 1,340,000 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Cellebrite DI in the first quarter worth approximately $22,428,000. Finally, Royal Bank of Canada grew its position in shares of Cellebrite DI by 11,705.0% in the 1st quarter. Royal Bank of Canada now owns 824,226 shares of the company's stock worth $16,015,000 after buying an additional 817,244 shares during the last quarter. Institutional investors own 45.88% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Needham & Company LLC lowered their price objective on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, August 14th. JPMorgan Chase & Co. reduced their target price on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Finally, Lake Street Capital cut their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, August 15th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Trading Up 2.6%

NASDAQ CLBT traded up $0.44 on Monday, reaching $17.05. 1,823,280 shares of the company were exchanged, compared to its average volume of 1,695,688. Cellebrite DI Ltd. has a fifty-two week low of $13.10 and a fifty-two week high of $26.30. The business's fifty day moving average price is $15.03 and its 200 day moving average price is $17.01. The stock has a market capitalization of $4.08 billion, a P/E ratio of -22.41, a price-to-earnings-growth ratio of 3.02 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The business had revenue of $113.28 million during the quarter, compared to analysts' expectations of $112.33 million. During the same period in the prior year, the firm posted $0.10 EPS. The business's quarterly revenue was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.